208 related articles for article (PubMed ID: 34164830)
21. Prognostic factors for primary cutaneous anaplastic large-cell lymphoma: a multicentre retrospective study from Japan.
Miyagaki T; Inoue N; Kamijo H; Boki H; Takahashi-Shishido N; Suga H; Shimauchi T; Kiyohara E; Hirai Y; Yonekura K; Takeuchi K; Sugaya M
Br J Dermatol; 2023 Oct; 189(5):612-620. PubMed ID: 37539944
[TBL] [Abstract][Full Text] [Related]
22. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
23. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
[TBL] [Abstract][Full Text] [Related]
24. Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes.
Mélard P; Idrissi Y; Andrique L; Poglio S; Prochazkova-Carlotti M; Berhouet S; Boucher C; Laharanne E; Chevret E; Pham-Ledard A; De Souza Góes AC; Guyonnet-Duperat V; Bibeyran A; Moreau-Gaudry F; Vergier B; Beylot-Barry M; Merlio JP; Cappellen D
Oncotarget; 2016 Oct; 7(42):68734-68748. PubMed ID: 27626696
[TBL] [Abstract][Full Text] [Related]
25. Lymphomatoid papulosis with 6p25.3 rearrangement: a further case of the newly described variant.
Kluk J; Child F; Robson A
Br J Dermatol; 2014 Dec; 171(6):1590-2. PubMed ID: 24804939
[No Abstract] [Full Text] [Related]
26. Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma.
Sanka RK; Eagle RC; Wojno TH; Neufeld KR; Grossniklaus HE
Ophthalmology; 2010 Feb; 117(2):343-51. PubMed ID: 19969358
[TBL] [Abstract][Full Text] [Related]
27. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME
Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362
[TBL] [Abstract][Full Text] [Related]
28. Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders.
De Souza A; Tinguely M; Pfaltz M; Burghart DR; Kempf W
J Cutan Pathol; 2014 Dec; 41(12):901-6. PubMed ID: 25353265
[TBL] [Abstract][Full Text] [Related]
29. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases.
Pham-Ledard A; Prochazkova-Carlotti M; Laharanne E; Vergier B; Jouary T; Beylot-Barry M; Merlio JP
J Invest Dermatol; 2010 Mar; 130(3):816-25. PubMed ID: 19812605
[TBL] [Abstract][Full Text] [Related]
30. Primary Cutaneous Anaplastic Large Cell Lymphoma With 6p25.3 Rearrangement and Epidermotropism.
Dutra E; Maia T; Cabeçadas J
Am J Dermatopathol; 2022 Mar; 44(3):196-197. PubMed ID: 34966054
[TBL] [Abstract][Full Text] [Related]
31. Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders.
Sciallis AP; Law ME; Inwards DJ; McClure RF; Macon WR; Kurtin PJ; Dogan A; Feldman AL
Mod Pathol; 2012 Jul; 25(7):983-92. PubMed ID: 22388754
[TBL] [Abstract][Full Text] [Related]
32. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
[TBL] [Abstract][Full Text] [Related]
33. Intralymphatic Spread Is a Common Finding in Cutaneous CD30+ Lymphoproliferative Disorders.
Ferrara G; Ena L; Cota C; Cerroni L
Am J Surg Pathol; 2015 Nov; 39(11):1511-7. PubMed ID: 26371781
[TBL] [Abstract][Full Text] [Related]
34. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM
Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794
[TBL] [Abstract][Full Text] [Related]
35. Acitretin combined with NB-UVB in the treatment of cutaneous CD30-positive anaplastic large cell lymphoma.
Xu H; Liu Q; Li YM; Ma H; Hu HM
Dermatol Ther; 2019 Mar; 32(2):e12834. PubMed ID: 30659723
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
Ferreira CR; Zhao S; Sanches JA; Miyashiro D; Cury-Martins J; Azevedo RS; Zerbini MCN; Natkunam Y; Gratzinger D
Diagn Pathol; 2019 Oct; 14(1):115. PubMed ID: 31640798
[TBL] [Abstract][Full Text] [Related]
37. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
Kempf W
Semin Diagn Pathol; 2017 Jan; 34(1):22-35. PubMed ID: 27993440
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous CD30-Positive Lymphoproliferative Disorders.
Kempf W
Surg Pathol Clin; 2014 Jun; 7(2):203-28. PubMed ID: 26837199
[TBL] [Abstract][Full Text] [Related]
39. CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group.
Paulli M; Berti E; Rosso R; Boveri E; Kindl S; Klersy C; Lazzarino M; Borroni G; Menestrina F; Santucci M
J Clin Oncol; 1995 Jun; 13(6):1343-54. PubMed ID: 7751878
[TBL] [Abstract][Full Text] [Related]
40. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
